Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cymbalta Advisory Committee Review In Chronic Pain Now Set For August

This article was originally published in The Pink Sheet Daily

Executive Summary

Rescheduled panel meeting could include discussion of statistical methods for dealing with missing patient data and safe use in a significantly broader population.

You may also be interested in...



Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning

The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.

Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning

The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.

Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data

A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs

Topics

UsernamePublicRestriction

Register

PS070991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel